| Page 166 | Kisaco Research

Explore h ow AI models predict protein 3D structures from sequences, enabling insights into folding pathways and functional conformations
Examine emerging co-folding models that reveal protein–protein interactions and guide multimeric complex design.

Author:

Miles Congreve

Chief Scientific Officer
Isomorphic Labs

Miles Congreve

Chief Scientific Officer
Isomorphic Labs

Learn how AI-driven approaches integrate multiomics data, including genomics, proteomics, and transcriptomics, to identify potential drug targets and disease biomarkers for complex diseases.
Explore how AI models synthesize cross-omic data and real-time multiomic information to uncover novel biological mechanisms, identify potential biomarkers and enable precision medicine.

Author:

Kiran Nistala

Head, Functional Genomics
Alkermes

Kiran Nistala

Head, Functional Genomics
Alkermes

Author:

David Hallett

Chief Scientific Officer
Recursion

David Hallett

Chief Scientific Officer
Recursion

Author:

Melissa Landon

Head, Commercial & Business Development, AI & Automation
MilliporeSigma

Melissa Landon

Head, Commercial & Business Development, AI & Automation
MilliporeSigma

Author:

Morten Sogaard

Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma

Morten Sogaard

Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma

Author:

Peter Clark

Vice President, Digital Chemistry & Design
Novo Nordisk RDUS

Peter Clark

Vice President, Digital Chemistry & Design
Novo Nordisk RDUS

Demonstrate how AI-driven initiatives - like predictive modelling and automated inspection -translate into measurable outcomes (e.g., defect reduction, shorter batch release cycles) that justify capital investment and cross-functional prioritization.

Learn how predictive simulations, generative AI and differentiating clinical biomarkers are forecasted to cut prototyping timelines by weeks and reduce per‑trial costs.

.

Author:

Gregory Goldmacher

Assistant Vice President, Clinical Research, Head, Imaging
Merck

Gregory Goldmacher

Assistant Vice President, Clinical Research, Head, Imaging
Merck

Author:

Pavan Choksi

Partner
Arkitek Ventures

Pavan Choksi

Partner
Arkitek Ventures

Author:

Tarun Walia

Senior Director, Decision Science
Novo Nordisk

Tarun Walia

Senior Director, Decision Science
Novo Nordisk

Learn how  GenAI is transforming early drug discovery by designing novel, drug-like small molecules with improved potency, selectivity, and ADME properties.
Explore how GenAI integrates with synthesis planning and automation tools to prioritize viable candidates and accelerate iterative drug development.

Author:

Philip Tagari

Chief Scientific Officer
Insitro

Philip Tagari

Chief Scientific Officer
Insitro

Author:

Yue-Wang Webster

Vice President, Model Driven Drug Discovery Platforms
Eli Lilly

Yue-Wang Webster

Vice President, Model Driven Drug Discovery Platforms
Eli Lilly

Discuss how AI is used to identify pathological features, discover drug targets, and decode complex disease biology at a systems level.

Author:

Ari Allyn-Feuer

Director, AI Intelligence Product
GSK

Ari Allyn-Feuer

Director, AI Intelligence Product
GSK

Author:

Arvind Rao

Associate Professor, Computational Medicine & Bioinformatics
University of Michigan

Arvind Rao

Associate Professor, Computational Medicine & Bioinformatics
University of Michigan